On June 2, 2023, the AGs of 41 states and Washington, D.C., filed a stipulation to resolve claims stemming from a 2016 lawsuit in which the AGs alleged that Virginia-based drug manufacturer Indivior had used anticompetitive tactics to illegally keep generic manufacturers out of the market and extend its monopoly on the opioid medication Suboxone. Specifically, the AGs alleged that Indivior had engaged in a practice known as “product hopping” by switching to an oral film version from a tablet version just as generic manufacturers were poised to begin marketing their own tablet versions.
The stipulation imposes disclosure requirements on Indivior when filing a citizen petition, filing a new drug application for a follow-on drug, beginning to market an FDA-approved drug, or for any change in corporate...
U.S. President Donald Trump said Wednesday that Iran had agreed not to execute eight women protesters, while Iranian officials and the judiciary denied any such executions had been planned and des...